摘要
在对新型冠状病毒肺炎患者治疗中,临床专家推荐达芦那韦可有效抑制新型冠状病毒,但目前其还未在相关指南中予以推荐。本文通过对达芦那韦进行文献综述,以期为治疗新型冠状病毒肺炎提供参考。
In the treatment of patients with COVID-19,some clinical experts suggested that darunavir might be effective in suppressing COVID-19,which,however,has not been included in any COVID-19 treatment guidelines.The current review of darunavir aims to provide references for the treatment of COVID-19.
作者
赵紫楠
郭思瑞
金鹏飞
杨莉萍
李可欣
胡欣
ZHAO Zi-nan;GUO Si-rui;JIN Peng-fei;YANG Li-ping;LI Ke-xin;HU Xin(Department of Pharmacy,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Hospital Clinical Trial Center,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences P.R.,Beijing 100730,China)
出处
《中国合理用药探索》
CAS
2020年第6期1-4,共4页
Chinese Journal of Rational Drug Use
基金
“国家重大新药创制”科技重大专项(2017zx09101001002002)。
